AvenCell
PrivateLast Round
Grant
Jun 30, 2025
Total Funding Raised
$362M
Momentum Score
25 /100
Company Overview
AvenCell is a biotechnology company specializing in T cell-based immunotherapies designed to enhance cancer treatment by developing chimeric antigen receptor T cells for precise targeting of cancer antigens, thereby expanding the range of treatable cancers, including solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AvenCell Comps
Public and private peers based on sector, stage, and business model.
AvenCell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 30, 2025 | ||||
| Series B | Oct 22, 2024 | ||||
| Series A | Jun 22, 2021 |
Key People
Founding team and executive leadership
AvenCell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Grant |
| Cellex Cell Professionals GmbH | Series A |
| F-Prime Capital | Series B |
| Eight Roads Ventures | Series B |
| Novo Holdings | Series B |
| Blackstone Life Sciences | Series B, Series A |
| Intellia Therapeutics | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2025
$40M grant received from Japan Agency for Medical Research and Development.
- Jun 30, 2025
Dual-antigen CAR-T therapy AVC203 for B-cell Lymphomas now at IND stage.
AvenCell Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AvenCell's valuation, stock price, and market status.
